Evolent Health Receives a Hold from Wells Fargo

By Jason Carr

Wells Fargo analyst Jamie Stockton maintained a Hold rating on Evolent Health (NYSE: EVH) yesterday. The company’s shares closed yesterday at $18.80.

According to TipRanks.com, Stockton is a 4-star analyst with an average return of 13.4% and a 54.5% success rate. Stockton covers the Technology sector, focusing on stocks such as Medidata Solutions, Castlight Health, and Quality Systems.

Evolent Health has an analyst consensus of Strong Buy, with a price target consensus of $35.

Based on Evolent Health’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $60.21 million and GAAP net loss of $11.21 million. In comparison, last year the company earned revenue of $40.41 million and had a GAAP net loss of $11.98 million.

Evolent Health, Inc. engages in the provision of health system solutions. It includes consulting, population health technology and clinical and operational capabilities. The company was founded by Frank Williams, Seth Blackley, Tom Peterson in August 2011 and is headquartered in Arlington, VA.